|
| miRNA | Type of DM | Study design | Study population | Profiling | Source | Significant comparisons-details | Reference |
|
| Diabetes microvascular complications |
↑ 661
↑ 571
↑ 770-5p
↑ 892b
↑ 1303 | DM2 | Case
Control | DMC+ ()
DMC− ()
Controls () | Yes | Serum | DM versus controls
DMC+ versus DMC− | [110] |
| ↑ 31 | DM2 | Case
Control | DMC ()
DM-CVD ()
DM () | Yes | Serum | DMC versus others | [111] |
| Diabetic retinopathy |
↓ 27b
↑ 320a | DM1 | Nested
Case
Control | Incidence of DR ()
Progression of DR ()
Controls () | Yes | Serum | 27b: OR: incidence of DR 0.57 (0.40, 0.82);
320: OR: incidence of DR 1.57 (1.07, 2.31), OR: progression of DR 1.43 (1.05, 1.94) | [112] |
| ↓ 126 | DM1 | Nested
Case
Control | Complications+ ()
Complications− () | Yes | Serum | OR: PDR 0.75 (0.59–0.95) | [113] |
↑ 21
↑ 181c
↑ 1179 | DM2 | Case Control | PDR ()
NPDR ()
Controls () | Yes | Serum | PDR versus NPDR | [115] |
| ↓ 126 | DM2 | Case
Control | PDR ()
NPDR ()
DR− ()
Controls () | No | Serum | PDR versus DR− | [114] |
| ↑ 93 | DM2 | Case
Control | DR+ ()
DR− ()
Controls () | No | Plasma | DR+ versus DR− | [117] |
| ↑ 21 | DM2 | Case
Control | PDR ()
NPDR ()
DR− ()
Controls () | No | Plasma | PDR and NPDR versus DR− | [116] |
↑ 23a
↑ 320a-b | DM2 | Case
Control | PDR ()
ME () | Yes | Vitreous/
serum | PDR versus ME | [138] |
| Diabetic nephropathy |
↓ let-7c
↓ 29a
↑ let-7b
↑ 21 | DM1 | Prospective: rapid progression to ESRF | Macro RP ()
Macro NP ()
Normo () | No | Plasma | let-7c: OR: 0.23 (0.10, 0.53)
29a: OR: 0.39 (0.20, 0.76)
let-7b: OR: 2.38 (1.31, 4.0)
21: OR: 5.87 (1.68, 20.46) | [118] |
| ↑ 217 | DM2 | Case
Control | Normo ()
Micro ()
Macro ()
Controls () | No | Serum | DM2 versus controls
Micro versus normo
Macro versus micro | [121] |
↑ 21
↑ 29a
↑ 192 | DM2 | Case
Control | Macro ()
Micro ()
Normo () | No | Serum | Macro versus micro and normo
CKD+ (n = 18) versus CKD− (n = 32) | [120] |
| ↓ 130 | DM2 | Case
Control | Normo ()
Micro ()
Macro ()
Controls () | No | Serum | Macro versus micro and normo
Micro versus normo
Controls versus others | [123] |
| ↓ let-7a | DM2 | Case
Control | DN− ()
DN+ ()
Controls () | Yes | Blood | DN+ versus DN− | [119] |
| ↓ 126 | DM2 | Case
Control | Normo ()
DM2-micro (n = 29)
DM2-macro ()
Controls () | No | Blood | Micro-macro versus controls and normo
Macro versus micro | [122] |
| Urinary miRNA in diabetic nephropathy |
| ↓ 15 | DM2 | Case
Control | CKD-IgAN ()
CKD-DN ()
CKD-HTN () | Yes | Urinary sediment | DN versus others CKD | [124] |
| ↓ 192 | DM2 | Case
Control | DN ()
MCN/FGS ()
MGN ()
Controls () | No | Urinary sediment | DN versus others | [125] |
↓ 2861
↓ 1915-3p
↓ 4532 | DM2 | Case
Control | DN+ ()
DN− () | Yes | Urine | DN+ versus DN− | [126] |
↓ 323b-5p
↑ 122-5p
↑ 429 | DM1 | Case
Control | Normo ()
Intermittent micro ()
Persistent micro () Macro () | Yes | Urine | Persistent versus intermittent micro | [127] |
| 105, 1972, 28, 30b, 363, 424, 486, 495, 548o | DM1 | Prospective: micro onset | Normo () | Yes | Urine | 9 miRNAs: molecular miRNA signature for microalbuminuria | [128] |
| 29a | DM2 | Case
Control | Macro/micro ()
Normo () | No | Urine | Macro/micro versus normo | [139] |
↑ 130a
↑ 145
↓ 155
↓ 424 | DM1 | Case
Control | Micro ()
Normo () | Yes | Urinary exosomes | Micro versus normo | [129] |
↑ 320c
↑ 6068 | DM2 | Case
Control | DN+ ()
DN− ()
Controls () | Yes | Urinary exosomes | DN+ versus DN− and controls | [130] |
↑ 133b
↑ 342
↑ 30a | DM2 | Case
Control | Macro ()
Micro ()
Normo ()
Controls () | No | Urinary exosomes | Macro and micro versus normo
(133b only macro versus micro) | [131] |
↑ 192
↑ 194
↑ 215 | DM2 | Case
Control | Normo ()
Micro ()
Macro ()
Controls () | No | Urinary MV | Micro versus normo, controls, and macro | [132] |
|
